|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
Clinical Therapy Trials—Drug |
Department of Medical Oncology and Clinical Haematology, Royal Melbourne Hospital, Parkville, Victoria, Australia 3050 (S.N., M.A.R.); Department of Medical Oncology and Clinical Haematology, Royal Children's Hospital, Parkville, Victoria, Australia 3050 (D.A); and Austin and Repatriation Medical Centre, Heidelberg, Victoria, Australia 3181 (L.C.)
1 Address correspondence and reprint requests to Siobhan Ng, M.D., Department of Medical Oncology and Clinical Haematology, Royal Melbourne Hospital, Parkville, Victoria, Australia 3050.
Abstract
Primary central nervous system lymphoma (PCNSL) in the immunocompetent patient reaches a peak incidence in the sixth and seventh decades of life. This retrospective study reviewed the efficacy and tolerability of high-dose methotrexate (HDMTX) in an elderly patient population. Between May 1995 and September 1998, ten consecutive elderly patients with histologically proven PCNSL were treated with HDMTX. The median age was 72.5 years and eight patients (80%) were older than 70 years. HDMTX was well tolerated with no episodes of grade 4 toxicity nor febrile neutropenia. Toxicity included grade 3 nausea (1), grade 2 mucositis (2), and grade 2 asymptomatic elevation of liver transaminases (2). Grade 1 toxicity occurred in three patients with nausea, diarrhea, and mild reversible elevation in serum creatinine in one patient each. Six patients had a complete response and three patients achieved a partial response, giving an overall response rate of 90% (95% confidence interval, 56%-100%). The median overall survival for the cohort was 36 months (range 4-43 months). In summary, HDMTX is well tolerated in this elderly population with PCNSL and achieves response rates and median survival comparable with other chemotherapy or radiotherapy regimens.
References
Abrey, L.E., DeAngelis, L.M., and Yahalom, J. (1998) Long-term survival in primary CNS lymphoma. J. Clin. Oncol. 16,859 -863.[Abstract]
Berry, M.P., and Simpson, W.J. (1981) Radiation therapy in the management of primary malignant lymphoma of the brain. Int. J. Radiat. Oncol. Biol. Phys. 7, 55-59.[Web of Science][Medline]
Blay, J.Y., Conroy, T., Chevreau, C., Thyss, A., Quesnel, N., Eghbali, H., Bouabdallah, R., Coiffier, B., Wagner, J.P., Le Mevel, A., Dramais-Marcel, D., Baumelou, E., Chauvin, F., and Biron, P. (1998) High dose methotrexate for the treatment of primary cerebral lymphomas: Analysis of survival and late neurologic toxicity in a retrospective series. J. Clin. Oncol. 16,864 -871.[Abstract]
Brada, M., Dearnaley, D., Horwich, A., and Bloom, H.J.G. (1990) Management of primary cerebral lymphoma with initial chemotherapy: Preliminary results and comparison with patients treated with radiotherapy alone. Int. J. Rad. Oncol. Biol. Phys. 18,787 -792.[Web of Science][Medline]
Cher, L., Glass, J., Griffith, G.R., and Hochberg, F.H.
(1996) Therapy of primary CNS lymphoma with methotrexate-based
chemotherapy and deferred radiotherapy: Preliminary results.
Neurology 46,1757
-1759.
DeAngelis, L.M., Yahalom, J., Thaler, H.T., and Kher, U.
(1992) Combined modality therapy for primary CNS lymphoma.
J. Clin. Oncol. 10,635
-643.
Eby, N.L., Grufferman, S., Flannelly, C.M., Schold, S.C., Jr., Vogel, F.S., and Burger, P.C. (1988) Increasing incidence of primary brain lymphoma in the U.S. Cancer 62,2461 -2465.[CrossRef][Web of Science][Medline]
Fine, H.A., and Mayer, R.J. (1993) Primary central
nervous system lymphoma. Ann. Int. Med.
119,1093
-1104.
Freilich, R.J., Delattre, J.Y., Monjour, A., and DeAngelis, L.M.
(1996) Chemotherapy without radiation therapy as initial
treatment for primary CNS lymphoma in older patients.
Neurology 46,435
-439.
Gabbai, A.A., Hochberg, F.H., Linggood, R.M., Bashir, R., and Hotleman, K. (1989) High dose methotrexate for non-AIDS primary central nervous system lymphoma. J. Neurosurg. 70,190 -194.[Web of Science][Medline]
Lutz, J.M, and Coleman, M.P. (1994) Trends in primary cerebral lymphoma. Br. J. Cancer 70,716 -718.[Web of Science][Medline]
Murray K., Kun L., and Cox J. (1986) Primary malignant lymphoma of the central nervous system: Results of treatment of 11 cases and review of the literature. J. Neurosurg. 65,600 -607.[Web of Science][Medline]
Nelson, D.F., Martz, K.L., Bonner, H., Nelson, J.S., Newall, J., Kerman, H.D., Thomson, J.W., and Murray, K.J. (1992) Non-Hodgkin's lymphoma of the brain: Can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int. J. Radiat. Oncol. Biol. Phys. 23,9 -17.[Web of Science][Medline]
Neuwelt, E.A., Goldman, D.L., Dahlborg, S.A., Crossen, J., Ramsey, F., Roman-Goldstein, S., Braziel, R., and Dana, B. (1991) Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: Prolonged survival and preservation of cognitive function. J. Clin. Oncol. 9,1580 -1590.[Abstract]
Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T., and Carbone, P.P. (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 5,649 -655.[Web of Science][Medline]
O'Neill, B.P., Wang, C.H., O'Fallon, J.R., Colgan, J.D., Earle, J.D., Krigel, R.L., Brown, L.D., and McGinnis, W.L. (1999) Primary central nervous system non-Hodgkin's lymphoma (PCNSL): Survival advantages with combined therapy? A final report of the North Central Cancer Treatment Group (NCCTG) Study 86-72-52. Int. J. Radiat. Oncol. Biol. Phys. 43,559 -563.[CrossRef][Web of Science][Medline]
Rosenthal, M.A., Sheridan W.P., Green, M.D., Liew, K., and Fox, R.M. (1993) Primary cerebral lymphoma: An argument for the use of adjunctive systemic chemotherapy in treatment. Aust. N. Z. J. Surg. 63,30 -32.[Web of Science][Medline]
Rosenthal, M.A., and Green, M.D. (1995) Cerebral lymphoma. In: Kaye, A.H., and Laws, E.R., Jr. (Eds.), Brain Tumors. Edinburgh: Churchill Livingstone. pp.841 -869.
Singh, A., Strobos, R.J., Singh, B.M., Rothballer, A.B., Reddy, V.,
Puljic, S., and Poon, T.P. (1982) Steroid-induced remissions in
CNS lymphoma. Neurology
32,1267
-1271.
CiteULike 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Sierra del Rio, A. Rousseau, C. Soussain, D. Ricard, and K. Hoang-Xuan Primary CNS Lymphoma in Immunocompetent Patients Oncologist, May 1, 2009; 14(5): 526 - 539. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Illerhaus, R. Marks, F. Muller, G. Ihorst, F. Feuerhake, M. Deckert, C. Ostertag, and J. Finke High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study Ann. Onc., February 1, 2009; 20(2): 319 - 325. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-J. Zhu, E. R. Gerstner, D. A. Engler, M. M. Mrugala, W. Nugent, K. Nierenberg, F. H. Hochberg, R. A. Betensky, and T. T. Batchelor High-dose methotrexate for elderly patients with primary CNS lymphoma Neuro-oncol, January 1, 2009; 11(2): 211 - 215. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Jahnke, A. Korfel, P. Martus, M. Weller, U. Herrlinger, A. Schmittel, L. Fischer, E. Thiel, and On behalf of the German Primary Central Nervous Sy High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma Ann. Onc., March 1, 2005; 16(3): 445 - 449. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ishikawa, M. Hasegawa, Y. Tamaki, K. Hayakawa, T. Akimoto, H. Sakurai, N. Mitsuhashi, H. Niibe, M. Tamura, and T. Nakano Comparable Outcomes of Radiation Therapy without High-dose Methotrexate for Patients with Primary Central Nervous System Lymphoma Jpn. J. Clin. Oncol., September 1, 2003; 33(9): 443 - 449. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Hoang-Xuan, L. Taillandier, O. Chinot, P. Soubeyran, U. Bogdhan, J. Hildebrand, M. Frenay, N. De Beule, J.Y. Delattre, and B. Baron Chemotherapy Alone as Initial Treatment for Primary CNS Lymphoma in Patients Older Than 60 Years: A Multicenter Phase II Study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group J. Clin. Oncol., July 15, 2003; 21(14): 2726 - 2731. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J.M. Ferreri, L. E. Abrey, J.-Y. Blay, B. Borisch, J. Hochman, E. A. Neuwelt, J. Yahalom, E. Zucca, F. Cavalli, J. Armitage, et al. Summary Statement on Primary Central Nervous System Lymphomas From the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002 J. Clin. Oncol., June 15, 2003; 21(12): 2407 - 2414. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Fliessbach, H. Urbach, C. Helmstaedter, H. Pels, A. Glasmacher, J. A. Kraus, T. Klockgether, I. Schmidt-Wolf, and U. Schlegel Cognitive Performance and Magnetic Resonance Imaging Findings After High-Dose Systemic and Intraventricular Chemotherapy for Primary Central Nervous System Lymphoma Arch Neurol, April 1, 2003; 60(4): 563 - 568. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Batchelor, K. Carson, A. O'Neill, S. A. Grossman, J. Alavi, P. New, F. Hochberg, and R. Priet Treatment of Primary CNS Lymphoma With Methotrexate and Deferred Radiotherapy: A Report of NABTT 96-07 J. Clin. Oncol., March 15, 2003; 21(6): 1044 - 1049. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Fathallah-Shaykh Darts in the Dark Cure Animal, but Not Human, Brain Tumors Arch Neurol, May 1, 2002; 59(5): 721 - 724. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
